Clinical

Articles

By July 2021, the FDA had approved or tentatively approved 470 generic versions of medications. 

Notable FDA Generic and Biologics Approvals During the Past Year 

Videos

Drs Thomas C. Blevins and Diana Isaacs share insight on unmet needs and the future treatment landscape of biosimilars in the treatment of patients with diabetes.

Future Directions for the Use of Biosimilars in Diabetes

Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.

Challenges to Biosimilar Adoption of Insulin Glargine-yfgn

Thomas C. Blevins, MD, ECNU, FACE, FNLA, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss the impact of interchangeable insulin biosimilars on biologic products in the marketplace for diabetes management.

Impact of Interchangeable Insulin Biosimilars on Cost of Biologics

Experts in diabetes management discuss data from key clinical trials—INSTRIDE 1, INSTRIDE 2, and INSTRIDE 3—and evaluate the use of insulin glargine-yfgn as an interchangeable product with biologics.

Results of INSTRIDE Studies for Diabetes Management

Thomas C. Blevins, MD, ECNU, FACE, FNLA, provides an overview of biosimilars and discusses interchangeability status among biosimilars such as for insulin glargine-yfgn for the management of diabetes.

Role of Interchangeable Biosimilars in the Management of Diabetes

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Thomas C. Blevins, MD, ECNU, FACE, FNLA, review FDA-approved basal insulins for the management of diabetes.

Basal Insulin Therapies for Diabetes Management

Prescription drug costs are a significant challenge for Americans, who are paying medication prices higher than any comparable nation. 

CMS Official Touts Cost Savings Through Generics, Biosimilars

There is now a mad scramble to gain interchangeable status for biosimilars, but the meaning and significance of this appellation haven't yet been worked out for health care consumers or the manufacturing community.

What Biosimilar Interchangeability Status Would Mean for Pharmacists

Women make up to 80% of health care decisions in the United States, but for
some, biosimilar knowledge is lacking.